文献速递新药、器械与细胞基因治疗研发临床试验与 GCP

Fidanacogene elaparvovec 基因治疗成人B型血友病

Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
PubMed 文献 · N Engl J Med · 2024-01-01

这项3期开放标签研究评估了Fidanacogene elaparvovec(含高活性凝血因子IX变体的AAV基因治疗载体)在成人B型血友病中的疗效与安全性。45例受试者接受5×10^11载体基因组拷贝/公斤体重剂量,治疗后所有出血事件的年化出血率较预防治疗导入期降低71%,主要终点显示非劣效且优效;15个月时平均凝血因子IX活性为26.9%,62%受试者因转氨酶升高或因子IX水平降低(或两者兼有)接受糖皮质激素。

要点

  • 所有出血事件年化率从基线4.42降至基因治疗后1.28,降低71%,显示对预防治疗的非劣效与优效。
  • 15个月时平均凝血因子IX活性为26.9%(中位数22.9%,范围1.9至119.0)。
  • 62%受试者因转氨酶升高或因子IX水平降低(或两者兼有)接受糖皮质激素,未观察到输注相关严重不良事件、血栓事件、因子IX抑制物或恶性肿瘤。

核心结论

  • Fidanacogene elaparvovec在B型血友病受试者中优于预防治疗,可减少出血并实现稳定的凝血因子IX表达。

研究设计与样本

  • 3期开放标签研究,纳入18至65岁、凝血因子IX水平≤2%且已接受至少6个月预防性凝血因子IX浓缩物治疗的男性B型血友病患者。
  • Fidanacogene elaparvovec以5×10^11载体基因组拷贝/公斤体重的剂量给药,主要终点为治疗后第12周至第15个月的年化出血率(治疗及未治疗出血事件)与预防治疗导入期的非劣效比较。
  • 45例受试者接受Fidanacogene elaparvovec,其中44例完成至少15个月随访。

主要发现

  • 所有出血事件的年化出血率从基线4.42(95%CI 1.80至7.05)降至基因治疗后1.28(95%CI 0.57至1.98),降低71%,治疗差异为-3.15次事件(95%CI -5.46至-0.83;P=0.008),显示非劣效与优效。
  • 15个月时,采用一步法SynthASil测定,平均凝血因子IX活性为26.9%(中位数22.9%,范围1.9至119.0)。
  • 28例受试者(62%)因转氨酶升高或凝血因子IX水平降低(或两者兼有)自第11至123天开始接受糖皮质激素治疗。
  • 未观察到输注相关严重不良事件、血栓事件、凝血因子IX抑制物产生或恶性肿瘤。
  • 316例男性接受导入研究筛选,204例(64.6%)不符合条件,其中188例(59.5%)因存在抗AAV中和抗体而不符合条件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fidanacogene elaparvovec, an adeno-associated virus (AAV) gene-therapy vector for hemophilia B containing a high-activity human factor IX variant (FIX-R338L/FIX-Padua), was associated with sustained factor IX activity in a phase 1-2a study. METHODS: We conducted a phase 3 open-label study of fidanacogene elaparvovec at a dose of 5×1011 vector genome copies per kilogram of body weight. Men 18 to 65 years of age with hemophilia B and a factor IX level of 2% or less were eligible for screening if they had received at least 6 months of therapy with prophylactic factor IX concentrate. The primary end point, tested for noninferiority, was the annualized bleeding rate (treated and untreated bleeding episodes) from week 12 to month 15 after treatment with fidanacogene elaparvovec as compared with the prophylaxis lead-in period. Superiority, additional efficacy end points, and safety were also assessed. RESULTS: Of 316 men who underwent screening for the lead-in study, 204 (64.6%) were not eligible; 188 (59.5%) of those were ineligible owing to the presence of anti-AAV neutralizing antibodies. Of the 45 participants who received fidanacogene elaparvovec, 44 completed at least 15 months of follow-up. The annualized rate of bleeding for all bleeding episodes decreased by 71%, from 4.42 (95% confidence interval [CI], 1.80 to 7.05) at baseline to 1.28 (95% CI, 0.57 to 1.98) after gene therapy, a treatment difference of -3.15 episodes (95% CI, -5.46 to -0.83; P = 0.008). This result shows the noninferiority and superiority of fidanacogene elaparvovec to prophylaxis. At 15 months, the mean factor IX activity was 26.9% (median, 22.9%; range, 1.9 to 119.0) by one-stage SynthASil assay. A total of 28 participants (62%) received glucocorticoids for increased aminotransferase levels or decreased factor IX levels (or both) starting between 11 and 123 days. No infusion-related serious adverse events, thrombotic events, development of factor IX inhibitors, or malignant conditions were observed. CONCLUSIONS: Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and stable factor IX expression. (Funded by Pfizer; BENEGENE-2 ClinicalTrials.gov number, NCT03861273.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Cuker A, Kavakli K, Frenzel L, et al. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. N Engl J Med. 2024. PMID: 39321362. doi:10.1056/NEJMoa2302982

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。